Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Rating of “Hold” by Brokerages

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been assigned an average recommendation of “Hold” from the seven brokerages that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $6.2333.

A number of equities research analysts have recently commented on the company. Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Sunday, May 17th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, April 27th. Jefferies Financial Group reissued a “hold” rating and set a $3.70 target price on shares of Ironwood Pharmaceuticals in a research note on Thursday, February 26th. Citizens Jmp raised their target price on shares of Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Finally, Zacks Research lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th.

Ironwood Pharmaceuticals Stock Down 2.1%

IRWD opened at $3.22 on Wednesday. The stock has a market cap of $525.05 million, a P/E ratio of 5.37 and a beta of 0.25. Ironwood Pharmaceuticals has a 12 month low of $0.58 and a 12 month high of $5.78. The company has a fifty day simple moving average of $3.82 and a 200 day simple moving average of $3.87.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its earnings results on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%.The business had revenue of $106.51 million for the quarter, compared to the consensus estimate of $92.11 million. On average, equities research analysts expect that Ironwood Pharmaceuticals will post 1.04 earnings per share for the current fiscal year.

Insider Activity at Ironwood Pharmaceuticals

In related news, Director Alexander J. Denner sold 6,730,800 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.05, for a total value of $20,528,940.00. Following the sale, the director directly owned 9,188,635 shares of the company’s stock, valued at approximately $28,025,336.75. The trade was a 42.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 9.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Segall Bryant & Hamill LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter valued at about $976,000. Bull Harbor Capital LLC acquired a new position in shares of Ironwood Pharmaceuticals during the first quarter worth about $48,000. EverSource Wealth Advisors LLC boosted its position in shares of Ironwood Pharmaceuticals by 48.7% during the first quarter. EverSource Wealth Advisors LLC now owns 20,336 shares of the biotechnology company’s stock worth $71,000 after buying an additional 6,656 shares during the period. Quantinno Capital Management LP grew its holdings in shares of Ironwood Pharmaceuticals by 9.1% during the first quarter. Quantinno Capital Management LP now owns 129,703 shares of the biotechnology company’s stock worth $455,000 after buying an additional 10,810 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp grew its holdings in shares of Ironwood Pharmaceuticals by 5.2% during the first quarter. OMERS ADMINISTRATION Corp now owns 226,310 shares of the biotechnology company’s stock worth $794,000 after buying an additional 11,200 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial?stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.